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We have previously described a selective increase in HIV-DNA content in CCR5-negative lymphocytes from late stage HIV-infected patients.
Here, we show that this increase occurred even in the absence of viral phenotypic switching from CCR5- to CXCR4-tropic. This leads us to
hypothesize that early and late CCR5-tropic viruses might be different in the ability to infect CCR5-low or -negative cells. We compared a set of
early CCR5-tropic viruses with low viral DNA content in CCR5-negative cells to a set of late CCR5-tropic viruses with high viral DNA content in
CCR5-negative cells. We could not find any significant differences between the two sets of viruses in the aspects of relative infectivity in CCR5-
low cells and the level of inhibition by h-chemokine. This suggested that there may be some changes in cellular phenotype or environment that
allows an expansion of susceptible cell population in late stages HIV infection. Understanding these changes may provide a novel approach for
HIV therapy.
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HIV-1 interacts with two receptors on surface of the target
cells for infection, the CD4 receptor and the coreceptor. Two
major types of HIV-1 coreceptor are CXCR4 and CCR5.
CXCR4 is more wildly expressed and present on both naive
and memory cells and binds a CXC chemokine, stromal cell
derived factor-1 (SDF-1). CCR5 is a CC chemokine receptor
that binds macrophage inflammatory protein (MIP-1a, MIP-
1h) and RANTES (regulated upon activation, normal T cell
expressed and secreted). It is predominantly expressed on
macrophage, dendritic cells, brain microglial cells and
memory T cells but absent on most T-cell lines. Almost all
HIV-1 strains use either CCR5 or CXCR4 or both (Berger et
al., 1999; Unutmaz and Littman, 1997). Other receptors have
been identified (CCR2b, CCR3, CCR8, STRL33/BONZO,0042-6822/$ - see front matter D 2005 Elsevier Inc. All rights reserved.
doi:10.1016/j.virol.2005.12.003
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E-mail address: sipaw@mahidol.ac.th (P. Auewarakul).BOB/GPR15 etc.), but they support the entry of few HIV-1
isolates and less efficient than CCR5 and CXCR4 (Cairns and
D’Souza, 1998). Viral isolates using CCR5 are termed R5
viruses, while those using CXCR4 are X4 viruses and viruses
able to use both coreceptors are called R5X4 viruses (Moore
et al., 2004). R5 viruses play the dominant role in disease
transmission and in the early phase of infection, while X4
viruses emerge in late stages of infection. Viruses isolated
early in the course of disease typically use CCR5, whereas
many viruses isolated late in the course of disease can use
CXCR4 alone or both CCR5 and CXCR4 (Koot et al., 1999;
Simmons et al., 1996). There are several studies showing that
the disease progression strongly correlated with the CXCR4
usage.
We have previously described an increase of HIV-1 DNA
load in the CCR5-negative peripheral blood lymphocytes from
late stage AIDS patients (Auewarakul et al., 2001). Since this
increase was observed in all the late stage cases, it is unlikely
that this was due to the R5 to X4 phenotypic switching, which
is expected to be observed in about half of late stage cases. Our6) 372 – 378
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switching could not be accounted for all the viral DNA load
increase in CCR5-negative cells. We therefore hypothesized
that there might be an increase of infection by R5 virus in
CCR5-low or -negative cells in late stage infection. This
infection would theoretically be caused by either increased
cellular susceptibility to the infection or increased infectivity of
late R5 viruses, probably by increasing affinity to CCR5 and
resistance to h-chemokine.
This study sought to better understand the mechanisms by
which late R5 viruses infect CCR5-negative cell population.
We tested whether late R5 viruses may have intrinsic
properties that are distinct from early R5 viruses. We
isolated viruses from individuals at early and late stages of
infection and compared the infectivity in cells that expressed
different level of CCR5 and compared h-chemokine
(RANTES) sensitivity in low level CCR5-expressing cells.
Results
HIV-DNA contents in CCR5-positive and CCR5-negative cell
populations
Thirteen early and twenty-six late HIV-infected blood
samples were collected (Table 1). CD4 counts of early and
late samples ranged from 211 to 781 (386 T 157) (mean T
standard deviation) cells/mm3 and from 1 to 161 (42 T 46.3)
cells/mm3, respectively. Of 13 early samples, 11 samples
were identified as R5 and 2 samples were R5X4 isolates. On
the other hand, 8, 14 and 4 samples of late samples were R5,
R5X4, and X4, respectively. We found that HIV-DNA levels
in CCR5-negative cells of early samples (221 T 104 copies/
105 CD4+ cells) were markedly lower than those of late
samples with R5 viruses (11,720 T 12,799) or R5X4/X4
viruses (8095 T 8402) (P < 0.01). In contrast, there was no
significant difference between the viral DNA contents in
CCR5-negative cells from late samples harboring R5 and
R5X4/X4 viruses (P = 0.44). In CCR5-positive cells, there
was no significant difference in the viral DNA contents
between early samples with R5 viruses (2832 T 2604) and
late samples with R5 viruses (5563 T 3229) (P = 0.10) and
late samples with R5X4/X4 viruses (7408 T 8522) (P = 0.11).
The ratio of HIV-DNA in CCR5+/CCR5 cells in early
samples were about 8-fold higher than late R5 samples and
late R5X4/X4 (P < 0.01). The average of HIV-DNA ratio in
early R5, late R5 and late R5X4/X4 were 13.41 T 14.18, 1.48 T
1.93 and 1.48 T 1.73, respectively. There was no difference
in the DNA ratio between late R5 and late R5X4/X4
samples (P = 0.91).There was a minimal correlation between
viral DNA contents in CCR5-positive cells with CD4 counts
of all samples (P = 0.02) (Fig. 1A), in contrast, viral DNA
contents in CCR5-negative cells had a strong inverse
correlation with CD4 count (Pearson correlation = 0.47,
P < 0.01) (Fig. 1B).
To investigate whether these CCR5-negative cells harbor-
ing HIV-DNA were recently infected, we quantified 2-LTR
circle DNA form in both early and late R5 DNA samples. Wefound that the 2-LTR level in CCR5-positive and -negative
cells of late R5 samples were 888 T 531 and 1737 T 1503
copies/105 CD4 cells, respectively. The ratios of 2-LTR to
total DNA in CCR5-positive (0.21 T 0.15) and -negative cells
(0.17 T 0.07) of late samples were not different (P = 0.92). 2-
LTR level in CCR5-positive and -negative cells of early
samples were 457 T 395 and 43 T 25 copies/105 CD4 cells,
respectively. The ratio of 2-LTR circles to total HIV-DNA of
CCR5-positive (0.20 T 0.11) and -negative cells (0.21 T 0.15)
was not different (P = 0.87). The copy numbers of 2-LTR
circle DNA therefore showed similar increase in CCR5-
negative cells in late stages of infection, indicating an
increased new infection and susceptibility in this cell
population.
Relative infectivity of early and late R5 viruses in low
CCR5-expressing cells
The high viral DNA contents in CCR5-negative lympho-
cytes from late stages patients despite the R5 phenotype of the
viruses raised a hypothesis that late R5 viruses might infect
CCR5-low or -negative cells more readily than early R5
viruses. To test this hypothesis, 5 late R5 isolates were
compared with 7 early R5 isolates by infection using equal
amount of input p24 in CCR5-low cells. There was no
significant difference in p24 production between early R5
and late R5 isolates in high level CCR5-expressing cells (P =
0.57) and low level CCR5-expressing cells (P = 0.81) (Table
2). Accordingly, the ratios of p24 production in high and low
CCR5-expressing cells were not different between early and
late R5 isolates (P = 0.81). Nevertheless, there was a
substantial variation in this ratio (1.52–18.05) among the
tested viruses indicating heterogeneity in the relative viral
infectivity in cells with different level of CCR5. However, this
viral heterogeneity might not strongly affect the efficiency of
infection in vivo.
Sensitivity of early and late R5 viruses to b-chemokine
inhibition
The h-chemokines MIP-1a, MIP-1h and RANTES are
important defenses against HIV. Previously published data
suggested that there might be variability in the sensitivity to
inhibition by h-chemokine among different HIV-1 isolates
(Jansson et al., 1999; Karlsson et al., 2004; Koning et al.,
2003; Torre et al., 2000). We questioned whether such
variability might be responsible for the increased HIV-DNA
in CCR5-negative cells in late stages of infection. To test the
hypothesis, low CCR5-expressing HeLa cells (JC10) and
PHA-activated PBMCs were infected with the 7 early and 5
late R5 isolates in the presence and absence of RANTES.
Although significant variability in the sensitivity to RANTES
was observed in JC10 among the isolates, there was only a
slight difference between the IC50 of early R5 isolates
(162.85 T 95.86 ng/ml) and late R5 isolates (253.2 T 55.23
ng/ml) with no statistical significance (P = 0.12) (Fig. 2).
Additionally, RANTES IC50s in PHA-activated PBMC were
Table 1
Early and late samples with HIV-DNA contents and CD4 counts
Sample numbers Phenotypea Selected
samplesb
HIV-DNA load in
CCR5-positive cells
(copies/105 CD4+ cells)c,d
HIV-DNA load in
CCR5-negative cells
(copies/105 CD4+ cells)
HIV-DNA ratios of
CCR5+/CCR5 cells
CD4 counts
(cell/mm3)
Early samples
AN1 R5 Early1 1850 T 270 263 T 35 7.03 379
AN2 R5 Early2 2365 T 152 147 T 17 16.09 530
AN4 R5 Early3 5389 T 519 361 T 43 14.93 270
AN21 R5 Early4 7757 T 754 158 T 45 49.09 331
AN23 R5 3986 T 629 443 T 55 9.00 211
AN25 R5 Early5 488 T 26 125 T 21 3.90 308
AN26 R5 Early6 1068 T 32 253 T 34 4.22 445
AN27 R5 615 T 106 128 T 27 4.80 370
AN28 R5 840 T 193 131 T 4 6.41 244
AN29 R5 Early7 6256 T 1030 212 T 18 29.51 423
AN30 R5 534 T 229 208 T 23 2.57 503
AN3 R5X4 nde nd nd 781
AN5 R5X4 nd nd nd 220
Average 2832 T 2604 221 T 104 13.41 T 14.18 386 T 157
Late samples
CN6 R5 Late1 592 T 156 34,853 T 1930 0.02 57
CN14 R5 Late2 3982 T 540 4311 T 231 0.92 82
CN24 R5 11,910 T 1581 8914 T 423 1.34 9
CN27 R5 Late3 6163 T 704 4852 T 1122 1.27 114
CN28 R5 Late4 5816 T 1553 28,955 T 1832 0.20 52
CN31 R5 Late5 4025 T 514 2894 T 131 1.39 50
CN32 R5 7087 T 233 1166 T 98 6.08 101
CN37 R5 4930 T 1027 7814 T 1350 0.63 5
Average 5563 T 3229 11,720 T 12,799 1.48 T 1.93 59 T 39
CN4 R5X4 2143 T 71 7862 T 218 0.27 56
CN11 R5X4 18,069 T 3555 4381 T 471 4.12 2
CN12 R5X4 29,618 T 1874 11,890 T 834 2.49 10
CN13 R5X4 4332 T 176 30,417 T 2688 0.14 15
CN16 R5X4 2345 T 87 1215 T 20 1.93 53
CN18 R5X4 12,862 T 1534 3181 T 455 4.04 2
CN20 R5X4 9874 T 1040 13,138 T 289 0.75 5
CN23 R5X4 4094 T 449 3812 T 162 1.07 6
CN25 R5X4 1162 T 42 904 T 12 1.29 6
CN30 R5X4 18,808 T 993 17,384 T 2930 1.08 1
CN33 R5X4 927 T 31 7235 T 1830 0.13 35
CN34 R5X4 733 T 71 2857 T 215 0.26 136
CN35 R5X4 18,035 T 558 2853 T 433 6.32 1
CN36 R5X4 1135 T 43 1078 T 25 1.05 161
CN17 X4 2102 T 323 7469 T 136 0.28 11
CN38 X4 4331 T 1090 24,152 T 3768 0.18 7
CN40 X4 1278 T 302 1529 T 195 0.84 90
CN41 X4 1500 T 398 4345 T 306 0.35 20
Average 7408 T 8522 8095 T 8402 1.48 T 1.73 34 T 48
a Phenotypes of HIV-1 isolated were assayed by using GHOST cells which were co-transfected with human CD4 and either specific coreceptor CXCR4 or CCR5.
b Selected R5 isolates which were tested in relative infectivity and RATES blocking assay.
c CD4+ cells were calculated by using % CD4 in lymphocyte population.
d Mean T standard deviation.
e nd = not done.
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R5 viruses (280 T 44.72) (P = 0.75).
Discussion
Increased viral load and viral production is a major factor
contributing to the rapid destruction of CD4+ T cells and the
collapse of the immune system in late stages HIV disease.
Beside the lack of effective control by the immune response,expansion of infected cell population is likely to be a major
contributing factor for the increased viral production. Our data
indicated that the expansion of target cell population was
largely due to the increased infection in CCR5-negative
lymphocytes, while CCR5-positive cells contributed only
minimally to the expansion of infected cells in late stages of
infection. This suggested that CCR5-positive cells were
probably infected to almost maximum degree early in the
infection, while CCR5-negative cells were not susceptible to
Fig. 1. Scatter plots showing the correlation between CD4 count and HIV-DNA content (in log scale) in CCR5-positive (A) and CCR5-negative (B) peripheral blood
lymphocytes with early R5 (squares), late R5 (triangles), late R5X4 (diamonds) and late X4 (asterisks). CCR5-positive and CCR5-negative cell populations were
separated by Dynal-immunomagnetic technique, and the HIV-DNA content was measured by a gag quantitative competitive PCR. Pearson correlation and P value of
all samples were shown.
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later stages. This increased susceptibility was therefore likely to
be an important determining factor in the disease progression.
In contrast to the common belief that this increased suscepti-
bility and the expansion of target cell population is a result of
the viral R5 to X4 phenotypic switching, we showed here that
the expansion could occur without the phenotypic switching. In
fact, we could not find any difference in the viral DNA load in
CCR5-negative cells between late samples with R5 and X4/
R5X4 viruses. The most likely explanation for this phenomenon
was that late R5 viruses could infect CCR5-low or -negative
cells by an adaptation to use low CCR5 density for entry as had
been previously shown in some laboratory-adapted variants
(Chanel et al., 2002; Dejucq et al., 1999; Gorry et al., 2002;
Peters et al., 2004). However, our set of late R5 viruses did not
show any increased infectiveness in CCR5-low cells as
compared to the early R5 viruses.
Previous studies showed that R5 viruses could down-
regulate CCR5 coreceptor after infection (Karlsson et al.,
2005; Michel et al., 2005). It may provide an explanation for
the increased viral DNA in CCR5-negative cells if the viruses
had different efficiency in CCR5 down-regulation. To test this
hypothesis, we measured CCR5-negative cell fraction inGHOST-CCR5 cells after infection with the R5 viruses. We
found no difference in the numbers of CCR5-negative cells
after infection with early or late R5 isolates (data not shown).
Therefore, CCR5 down-regulation was not the mechanism
responsible for the observed increased in HIV-DNA in CCR5-
negative cells.
Another possible explanation is an increased resistance to h-
chemokine probably by optimizing the affinity of the viral
envelope to CCR5 as has been previously reported (Koning et
al., 2003). Cells with low density of surface CCR5 are more
efficiently protected against HIV infection by h-chemokine
(Paxton et al., 1999) and may be more likely to be influenced
by the viral changes invading this protection. We therefore
tested the sensitivity to h-chemokine blocking of the early and
late R5 viruses in CCR5-low cells and PHA-activated PBMC.
Although a small and statistically insignificant difference
between the early and late R5 viruses regarding the sensitivity
to h-chemokine was observed in JC10, it is unlikely that this
was responsible for the difference in viral DNA load in CCR5-
negative lymphocytes.
In summary, we did not find a significant difference in the
property of early and late R5 viruses that could explain the
difference in the viral DNA load in CCR5-negative lympho-
Table 2
Relative infectivity of early and late R5 isolates in high and low CCR5-expressing HeLa cells
Isolates P24 production (pg/ml) Ratios Statistics
HeLa cell (high)a HeLa cell (low)b
Early1 55.45 T 15.87 12.81 T 4.71 4.33
Early2 210.70 T 13.99 20.88 T 2.41 10.09
Early3 145.49 T 6.52 13.81 T 5.05 10.53
Early4 4347.54 T 93.52 324.55 T 12.69 13.40
Early5 127.21 T 13.46 13.39 T 5.32 9.50
Early6 38.46 T 9.10 16.51 T 6.54 2.33
Early7 15,816.15 T 3349.15 1131.21 T 272.48 13.98
2963 T 5883.34 219.02 T 418.41 9.17 T 4.36
P = 0.81c
Late1 31,128.28 T 5836.99 1724.54 T 59.42 18.05
Late2 20.50 T 2.72 6.12 T 1.31 3.35
Late3 35.24 T 8.19 23.19 T 14.44 1.52
Late4 360.60 T 35.91 27.73 T 2.55 13.00
Late5 65.29 T 47.98 11.94 T 3.91 5.47
6321.98 T 13,867.84 358.70 T 763.57 8.28 T 6.99
P = 0.57d P = 0.81d
a JC53 contains 150,000 CD4 molecules/cell and 150,000 CCR5 molecules/cell.
b JC10 contains 150,000 CD4 molecules/cell and 6000 CCR5 molecules/cell.
c P value of P24 protein ratio of high and low in early and late R5 isolates.
d P values of nonparametric Mann–Whitney U test of P24 production of early R5 and late R5 isolates in high and low cells.
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load was not due to a viral change but a result of an increased
cellular susceptibility of CCR5-negative T cells to the viral
infection or a decreased effectiveness of a defensive mecha-
nism selectively for CCR5-low cells. We have previously
reported an increase in activation status of CCR5-negative
CD4-positive lymphocytes in late stage infection and hypoth-
esized that this increased cellular activation may cause an
increased viral susceptibility of these cells, which may explain
the observed increased viral DNA in CCR5-negative cellsFig. 2. Scatter plot showing RANTES IC50 of early R5 and late R5 isolates.
The assay was performed in low CCR5-expressing HeLa cell (JC10). Each dot
represents the IC50 value of an early R5 or late R5 isolate. The mean IC50
value of each set is depicted by a horizontal line. P value of nonparametric
Mann–Whitney U test was shown.(Auewarakul et al., 1999). Production of h-chemokines
(RANTES, MIP-1a, MIP-1h) is a defensive mechanism
against R5 viruses. Levels of the chemokines needed for
effective viral inhibition in PBMC and cell lines expressing
high levels of CCR5 are generally much higher than what was
detected in plasma even after activation (Ullum et al., 1998). It
is therefore possible that the defense by h-chemokine is
effective only for cells with low CCR5 density, which require
lower level of h-chemokine for protection. Low h-chemokine
production in late stage infection might therefore selectively
allow more efficient infection in CCR5-low cells. Previous data
showing a reverse relationship between h-chemokine levels
and disease progression are consistent with this hypothesis
(Jansson et al., 1999; Karlsson et al., 2004; Koning et al.,
2003). Further studies are required to understand this complex
changes that may play a crucial role in the disease progression.
Materials and methods
Blood specimens and cell separation
All blood samples were collected from HIV-1-infected
individuals seeking medical care in HIV clinic of Siriraj
Hospital in Bangkok. Twenty-six EDTA-blood samples were
from AIDS patients attending the HIV clinic. Another 13
samples were from asymptomatic HIV-1 positive subjects
attending antenatal care unit. The first group was identified as
the late stage HIV infection. Their CD4 counts were lower than
200 cells/mm3, while the other group, early stage HIV-1
infection, had CD4 counts of higher than 200 cells/mm3.
Subjects that received antiretroviral drug therapy were exclud-
ed. Ten milliliters of peripheral venous blood was collected in
sterile EDTA vaccutainers and processed within 3 h after
collection. CD4 count was performed on whole blood sample.
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on Ficoll density cushion. After setting aside 106 PBMC cells
for HIV-1 coculture, the remaining cells were suspended in
RPMI 1640 medium with 10% fetal bovine serum (FBS) and
incubated overnight in culture flasks at 37 -C with 5% CO2 to
eliminate of monocytes. Non-adherent cells were further
separated by Dynal immunomagnetic beads (Dynal A. S, Oslo,
Norway) and the anti-CCR5 monoclonal antibody (2D7). The
separation was done according to the manufacturer’s instruc-
tion. The washing step was repeated 3 times to get maximum
purity.
Quantitative PCR
DNA of each CCR5-positive and negative PBMC subsets
was extracted by using QIAamp blood mini kit (QIAGEN).
The PCR was performed in one round by using SK38/SK39 as
the primers. In competitive PCR, wild type template was co-
amplified with increasing copy number of known amounts of
18-bp deletion competitors as previously described (Menzo et
al., 1992; Sangsiriwut et al., 2001). PCR was performed in the
total volume of 50 Al containing 1 PCR buffer, 1.5 mM
MgCl2, 200 AM of the dNTPs, 400 nM of each primer and 2.5
U of Taq DNA polymerase. PCR reactions were run at 95 -C
for 5 min and followed by 35 cycles of 95 -C for 30 s, 55 -C
for 30 s and 72 -C for 30 s. The PCR products of wild type
(115 bp) together with competitor (97 bp) were run in 10%
polyacrylamide gel and stained with ethidium bromide. The
relative intensity in each lane was measured by digital camera,
and the peak areas were calculated by Genetool computer
software (Syngene). The assay was performed in triplicate.
2-LTR circle quantification
2-LTR circles were amplified by quantitative real-time PCR
using a Light Cycler Instrument (Roche Diagnositics GmbH,
Germany) as previously described (Brussel et al., 2003).
Amplification was performed in a 20 Al reaction containing
1 Light Cycler Fast start DNA Master SYBR Green I, 400
nM of each forward (HIV-F) and reverse primers (HIV-R1)
spanning the LTR-LTR junction. PCR reactions were started
with initial denaturation step (95 -C for 10 min), 2-LTR
junctions were amplified for 15 cycles of 95 -C for 10 s, 66 -C
for 10 s and 72 -C for 10 s, and followed by 35 cycles at the
beginning of the annealing temperature were decreased by 0.5
-C per cycle to the secondary target temperature (59 -C). Copy
number of 2-LTR circles was determined by comparing with
the known standard 2-LTR curve.
HIV-1 coculture and coreceptor usage testing
The 106 separated PBMC were mixed together with equal
number of 3 days PHA-activated donor PBMC in RPMI 1640
with 10% FBS and 20 U of IL-2/ml. At day 3, 5  106 PHA-
activated PBMCs were added, and the culture was maintained
for a maximum of 5 weeks. On day 7, 14, 21, 28 and 35, the
culture supernatants were collected and tested for p24 HIV-1capsid antigen by an antigen-capture ELISA (Vironostika,
Organon Teknika). To determine the coreceptor usage, super-
natant from HIV coculture was inoculated into GFP-human
osteosarcoma cell lines (GHOST), which were stable cell lines
expressing human CD4 and either specific coreceptor CXCR4
or CCR5. After removing supernatant, GHOST cells were
cultured in DMEM medium supplemented with 2% FBS, G418
(500 Ag/ml), puromycin (1 Ag/ml) and hygromycin (50 Ag/ml)
for 3 days. The viral infection was then detected by examining
the cells for GFP fluorescence with a fluorescent microscope.
Relative infectivity in high and low level CCR5-transfected
HeLa cell
High and low level CCR5-expressing HeLa cells were JC53
and JC10, respectively. These cells were kindly provided by
Kabat D, Oregon Health and Science University, Portland,
Oregon, USA. JC53 contained 150,000 CD4 molecules/cell and
150,000 CCR5 molecules/cell, whereas JC10 contained
150,000 CD4 molecules/cell and 6000 CCR5 molecules/cell
on cell surface. Cells were seeded onto 96 U-bottom cultured
plate wells and inoculated with viruses at an amount of 10 ng of
p24. After overnight incubation, input viruses were removed,
the cells were washed 3 times and maintained in fresh DMEM
medium with 2% FBS for 7 days. The supernatants were then
harvested, and the concentrations of p24 protein were measured.
The assay was performed in triplicate. The differences of p24
production in high and low CCR5 cells and the ratio of p24
from high and low cells of early and late R5 viruses were
analyzed by a nonparametric Mann–Whitney U test.
RANTES blocking assay
JC10 cells and 3 days PHA-activated PBMC were pre-
incubated for 3 h at 37 -C with two fold serial dilutions of
RANTES (300, 150, 75, 37.5, 18.75, 9.38 ng/ml) (BD
Phamingen, San Diego, CA). Viruses at 5 ng of p24 were
added, and the cultures were incubated overnight. Cells were
washed 3 times, and fresh 2% FBS/DMEM medium for JC10
and RPMI supplemented with 10% FBS and 20 U/ml IL-2 for
PBMC with appropriated RANTES concentration were added.
Production of p24 protein was measured in the supernatant
samples taken at day 3 for JC10 and day 7 for PBMC after
infection. The p24 levels were compared to the level of p24
from culture without RANTES to calculate percent inhibition.
All measurements were performed in duplicate. The differences
of 50% RANTES inhibitory concentration (IC50) of early and
late R5 isolates were analyzed by a nonparametric Mann–
Whitney U test. If the appropriate degree of inhibition was not
achieved at the highest RANTES concentration, a value >300
ng/ml was recorded, and in figure and statistical test, we
assumed these to be equal to 300 ng/ml.
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